NewcelX (NCEL) Liabilities and Shareholders Equity (2019 - 2025)
NewcelX (NCEL) posted quarterly Liabilities and Shareholders Equity of $11.4 million for Q4 2025, up 1167.44% year-over-year from $903000.0 in Q4 2024, and up 2382.65% quarter-over-quarter from $461000.0 in Q2 2025.
NewcelX (NCEL) Liabilities and Shareholders Equity (2019 - 2025) Analysis & Trends
NewcelX (NCEL) has reported Liabilities and Shareholders Equity for 7 consecutive years, with $11.4 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Liabilities and Shareholders Equity rose 1167.44% year-over-year to $11.4 million; the TTM figure through Dec 2025 stood at $14.2 million (up 97.11% YoY), while the FY2025 annual figure was $11.4 million, up 1167.44% from the prior year.
- Liabilities and Shareholders Equity advanced to $11.4 million in Q4 2025 per NCEL's latest filing, from $461000.0 in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $11.4 million in Q4 2025 and bottomed at $461000.0 in Q2 2025.
- Historically, Liabilities and Shareholders Equity has averaged $3.9 million across 5 years, with a median of $2.4 million in 2023.
- Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity slumped 75.11% — and 2025, when it jumped 1167.44%.
- NewcelX's Liabilities and Shareholders Equity stood at $5.8 million in 2021, then slumped by 38.44% to $3.5 million in 2022, then plunged by 35.0% to $2.3 million in 2023, then sank by 60.86% to $903000.0 in 2024, then surged by 1167.44% to $11.4 million in 2025.
- Business Quant data shows NCEL's Liabilities and Shareholders Equity at $11.4 million in Q4 2025, $461000.0 in Q2 2025, and $903000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | NewcelX | 12.54 Mn | 10.34 Mn | - | 11.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 11.45 Mn |
| Jun 30, 2025 | 461,000.00 |
| Dec 31, 2024 | 903,000.00 |
| Jun 30, 2024 | 1.43 Mn |
| Dec 31, 2023 | 2.31 Mn |
| Jun 30, 2023 | 2.58 Mn |
| Dec 31, 2022 | 3.55 Mn |
| Jun 30, 2022 | 2.06 Mn |
| Dec 31, 2021 | 5.76 Mn |
| Jun 30, 2021 | 8.27 Mn |
| Dec 31, 2020 | 1.21 Mn |
| Dec 31, 2019 | 696,429.00 |